ArticleCancer research communications2026
Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Gustave Roussy Immune (GRIm) score, based on the neutrophil-to-lymphocyte ratio, serum albumin, and lactate dehydrogenase, is a validated prognostic marker in patients receiving immune checkpoint blockers (ICB). We evaluated its prognostic value in patients treated with bispecific CD3 T-cell engagers (TCE) in phase I trials. We retrospectively analyzed prospectively collected data from 150 patients treated with TCEs alone or combined with ICBs across 11 phase I trials at the Drug Development Department, Gustave Roussy (June 2016-February 2025). Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier methodology and Cox regression models. Discriminatory performance was assessed using Harrell C-index. Among 150 patients, 127 (85%) had solid tumors, and 23 (15%) had hematologic malignancies; 81% were classified as low-risk GRIm score. Low GRIm score was associated with improved OS [hazard ratio (HR), 0.29; 95% confidence interval (CI), 0.17-0.47; P < 0.001; median OS, 17.6 vs. 5 months] and PFS (HR, 0.57; 95% CI, 0.36-0.89; P = 0.01; median PFS, 2.8 vs. 1.6 months). In solid tumors, the GRIm score remained prognostic for OS (HR, 0.41; P = 0.002) but not for PFS. In hematologic malignancies, it strongly predicted both OS (HR, 0.04; P < 0.001) and PFS. Multivariable analyses confirmed the GRIm score as independently prognostic for OS (HR, 0.29; P < 0.001) and PFS (HR, 0.60; P = 0.035). Similar findings were observed in patients receiving TCE in monotherapy. The GRIm score independently predicts outcomes in patients receiving TCEs in phase I trials and may support patient selection, particularly in hematologic malignancies. SIGNIFICANCE: This study validates the use of the GRIm score as a prognostic tool for patients treated with TCE in early-phase trials. It discriminates between low- and high-risk patients across solid and hematologic malignancies and supports the integration of simple biomarkers into patient selection and risk stratification for bispecific CD3 therapies, improving trial design and remaining feasible in routine clinical practice settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.